Text Size

Report of the TFOS/ARVO symposium on global treatments for dry eye disease: An unmet need

Sullivan D.A., Hammitt K.M., Schaumberg D.A., Sullivan B.D., Begley C.G., Gjorstrup P., Garrigue J.-S., Nakamura M., Quentric Y., Barabino S., Dalton M., Novack G.D.

  • 2012
  • Ocular Surface
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Boston, 02114, MA, United States; Sjögren's Syndrome Foundation, Bethesda, MD, United States; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; TearLab Corporation, San Diego, CA, United States; School of Optometry, Indiana University, Bloomington, IN, United States; Resolvyx Pharmaceuticals, Bedford, MA, United States; Novagali Pharma, Evry, France; Santen Pharmaceutical Co., Nara, Japan; Iris Pharma, La Gaude, France; Clinica Oculistica, Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy; Dalton and Associates, Reading, PA, United States; PharmadLogic, San Rafael, CA, United States

Related Publications

Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits

Mochizuki T.; Hata T.; Mori N.; Yamazaki T.; Noto T.; Mano H.

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022